

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show 8 Numbers](#)[Edit 8 Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
L14 and CD20	40

**Database:**

US Patents Full-Text Database  
US Pre-Grant Publication Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

**Search:**

L15

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** Tuesday, September 03, 2002   [Printable Copy](#)   [Create Case](#)

**Set Name Query**

side by side

**Hit Count Set Name**

result set

*DB=USPT,PGPB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=OR*L15 L14 and CD2040 L15L14 Idec.as.451 L14*DB=USPT; THES=ASSIGNEE; PLUR=YES; OP=OR*L13 5776456.pn. or 5789554.pn. or 5736137.pn.3 L13L12 L11 same (therap\$ or treat\$ or administ\$)21 L12L11 CD20 same CD2265 L11L10 L7 and (combin\$) same (antibod\$) same (therap\$ or treat\$ or administ\$)  
and autoimmun\$136 L10L9 L7 and (combin\$) same (antibod\$) and autoimmun\$226 L9L8 L7 and autoimmun\$249 L8L7 ('b-cell' or 'b-lymphocyt' or cd20 or cd22) same (combin\$)672 L7L6 L4 same (autoimmun\$)34 L6L5 L4 same (cd20 or cd22)106 L5L4 ('b-cell' or 'b-lymphocyt' or cd20 or cd22) same (combin\$ or multiple)  
same (antibod\$)457 L4L3 L2 and combin\$12 L3L2 L1 and cd2012 L2L1 hanna.in.811 L1

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 09:35:38 ON 03 SEP 2002)

FILE 'MEDLINE, PROMT' ENTERED AT 09:35:52 ON 03 SEP 2002

L1 911 S RITUXIMAB  
L2 911 DUP REM L1 (0 DUPLICATES REMOVED)  
L3 30 S L2 AND (SCLEROSIS OR NEUROPATHY OR MS)  
L4 167 S INTERFERON-ALPHA AND SCLEROSIS  
L5 167 DUP REM L4 (0 DUPLICATES REMOVED)  
L6 124 S L5 AND PY<2000  
L7 107 S L6 AND (MULTIPLE (1W) SCLEROSIS)  
L8 1 S L7 AND (RITUXAN OR RITUXIMAB OR CD20 OR CD21 OR CD19)

FILE 'MEDLINE' ENTERED AT 09:45:17 ON 03 SEP 2002

L9 55 S L7  
L10 42 S L9 AND PY<1999  
L11 3 S (MULTIPLE (1W) SCLEROSIS) AND REVIEW AND (RIFNA OR  
INTERFERON  
L12 78 S (MULTIPLE (1W) SCLEROSIS) AND (RIFNA OR INTERFERON-ALPHA OR  
R  
L13 45 S L12 AND PY<1999

L13 ANSWER 9 OF 45 MEDLINE  
 ACCESSION NUMBER: 1998005280 MEDLINE  
 DOCUMENT NUMBER: 98005280 PubMed ID: 9345420  
 TITLE: Treatment of relapsing-remittent **multiple sclerosis** with recombinant human interferon-alfa-2a: design of a randomised, placebo-controlled, double blind trial in Norway.  
 AUTHOR: Nyland H; Myhr K M; Lillas F; Smievoll A I; Riise T; Nortvedt M; Nilsen R  
 CORPORATE SOURCE: Department of Neurology, University of Bergen, Norway.  
 SOURCE: MULTIPLE SCLEROSIS, (1996 Jul) 1 (6) 372-5.  
 Journal code: 9509185. ISSN: 1352-4585.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 DOCUMENT TYPE: (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (MULTICENTER STUDY)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199712  
 ENTRY DATE: Entered STN: 19980109  
 Last Updated on STN: 19980109  
 Entered Medline: 19971212

L13 ANSWER 17 OF 45 MEDLINE  
 ACCESSION NUMBER: 97135767 MEDLINE  
 DOCUMENT NUMBER: 97135767 PubMed ID: 8981304  
 TITLE: Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in **multiple sclerosis**.  
 AUTHOR: Bongioanni M R; Durelli L; Ferrero B; Imperiale D; Oggero A; Verdun E; Aimo G; Pagni R; Geuna M; Bergamasco B  
 CORPORATE SOURCE: Clinica delle Malattie del Sistema Nervoso, Torino, Italy.  
 SOURCE: JOURNAL OF THE NEUROLOGICAL SCIENCES, (1996 Nov) 143 (1-2) 91-9.  
 Journal code: 0375403. ISSN: 0022-510X.  
 PUB. COUNTRY: Netherlands  
 DOCUMENT TYPE: (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199703  
 ENTRY DATE: Entered STN: 19970327  
 Last Updated on STN: 19970327  
 Entered Medline: 19970320

L13 ANSWER 20 OF 45 MEDLINE  
 ACCESSION NUMBER: 96338674 MEDLINE  
 DOCUMENT NUMBER: 96338674 PubMed ID: 8725985  
 TITLE: Natural alpha interferon in **multiple sclerosis**: results of three preliminary series.  
 AUTHOR: Squillacote D; Martinez M; Sheremata W  
 CORPORATE SOURCE: Viragen, Inc., Hialeah, Florida, USA.  
 SOURCE: JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, (1996 May-Jun) 24 (3) 246-57.  
 Journal code: 0346411. ISSN: 0300-0605.  
 PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199611  
ENTRY DATE: Entered STN: 19961219  
Last Updated on STN: 19961219  
Entered Medline: 19961122

L13 ANSWER 21 OF 45 MEDLINE

ACCESSION NUMBER: 96291029 MEDLINE  
DOCUMENT NUMBER: 96291029 PubMed ID: 8710065  
TITLE: **Interferon alpha-2a** treatment of  
relapsing-remitting **multiple sclerosis**:  
disease activity resumes after stopping treatment.  
AUTHOR: Durelli L; Bongioanni M R; Ferrero B; Ferri R; Imperiale  
D;  
CORPORATE SOURCE: Bradac G B; Bergui M; Geuna M; Bergamini L; Bergamasco B  
SOURCE: Clinica Neurologica I, Universita di Torino, Italy.  
NEUROLOGY, (1996 Jul) 47 (1) 123-9.  
Journal code: 0401060. ISSN: 0028-3878.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
(RANDOMIZED CONTROLLED TRIAL)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 199609  
ENTRY DATE: Entered STN: 19960919  
Last Updated on STN: 19960919  
Entered Medline: 19960912